EGFR and lung cancer: Because EGFR-mutated lung cancers are dependent on mutant EGFR, the EGFR tyrosine kinase inhibitors (TKIs) show promising therapeutic efficacy in patients with EGFR-activating mutations, such as exon 19 deletions and L858R point mutations [5].